Method of treating rheumatoid arthritis with low dose type ii collagen
CA 2222770 A1 · Owner: Trentham, David E. · Inventors: Weiner, Howard L.; Trentham, David E.; Hafler, David A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for treating rheumatoid arthritis in humans which comprises orally administering between about 5 to 25µg per day of type II collagen to a human in need of such treatment, for a period of time sufficient to decrease at least one clinical symptom selected from the group consisting of joint tenderness, joint swelling morning, stiffness, grip strength, and 50-foot walk time.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 23, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 23, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 23, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.